Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Evolus, Inc. (EOLS) Cash Flow Statement

Evolus, Inc. (EOLS) generated -$15.4M of operating cash flow over the twelve months to 2026-06-30, spent $6.5M on capital expenditure and had free cash flow of -$21.9M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

EOLSEvolus, Inc.Follow EOLS — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
463.0M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days
LineFY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Operating cash flow-93.4-57.9-33.4-84.9-34.0-18.0-42.3-15.4
Capital expenditure4.63.11.02.91.64.88.5-6.5
Free cash flow-98.0-61.0-34.4-87.9-35.6-22.8-50.7-21.9
Stock-based compensation9.510.69.610.816.522.320.7—

USD millions · SEC XBRL

Evolus, Inc. — questions

What is Evolus, Inc.'s operating cash flow?
-$15.4M over the twelve months to 2026-06-30.
How much does Evolus, Inc. spend on capital expenditure?
$6.5M over the twelve months to 2026-06-30.
What is Evolus, Inc.'s free cash flow?
-$21.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Evolus, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.